3-Methoxycatechol

3-Methoxycatechol

SCHEMBL29477155

COc1cccc(O)c1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 1.00
ALDH1A1 P00352 2/20 1.00
LMNA P02545 2/20 1.00
HPGD P15428 2/20 1.00
ALOX15 P16050 2/20 1.00
HSD17B10 Q99714 2/20 1.00
KDM4E B2RXH2 1/20 1.00
CYP3A4 P08684 1/20 1.00
MAPT P10636 1/20 1.00
ALOX12 P18054 1/20 1.00
MAPK1 P28482 1/20 1.00
CA1 P00915 4/20 0.68
CA2 P00918 4/20 0.68
TSHR P16473 1/20 0.68
TLR2 O60603 1/20 0.57
ERN1 O75460 1/20 0.57
TLR1 Q15399 1/20 0.57
TLR6 Q9Y2C9 1/20 0.57
ADAMTS4 O75173 1/20 0.55
EGFR P00533 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
3-Methoxycatechol SCHEMBL67332 1.00 TP53 (1.00) TP53ALDH1A1LMNAHPGDALOX15
3-Methoxycatechol SCHEMBL11796213 0.97 TP53 (0.95) TP53ALDH1A1LMNAHPGDALOX15
Syringol SCHEMBL156388 0.89 KDM4E (0.80) TP53ALDH1A1LMNAHPGDALOX15
3-Methoxycatechol SCHEMBL18396654 0.89 TP53 (0.79) TP53ALDH1A1LMNAHPGDALOX15
3-Methoxycatechol SCHEMBL29636518 0.89 TP53 (0.79) TP53ALDH1A1LMNAHPGDALOX15
Guaiacol SCHEMBL14921410 0.88 CA1 (0.82) TP53ALDH1A1LMNAHPGDALOX15
3-Methoxycatechol SCHEMBL3373824 0.87 TP53 (0.76) TP53ALDH1A1LMNAHPGDALOX15
Syringol SCHEMBL7610366 0.86 KDM4E (0.76) TP53ALDH1A1LMNAHPGDALOX15
Syringol SCHEMBL6049240 0.86 KDM4E (0.76) TP53ALDH1A1LMNAHPGDALOX15
Syringol SCHEMBL8986496 0.86 KDM4E (0.76) TP53ALDH1A1LMNAHPGDALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4076841-A1 BONDED ABRASIVE ARTICLE AND METHOD OF MAKING THE SAME 3M Innovative Properties Company (US) 2022-10-26 EP claimed
WO-2025104050-A1 POLYMER AND COMPOSITION COMPRISING THE SAME MERCK PATENT GMBH (DE) 2025-05-22 WO disclosed
US-20240381867-A1 BIO-OIL FRACTIONS COMPOSITION DERIVED FROM BIO-OIL SUZANO S.A. (BR) 2024-11-21 US disclosed
WO-2024189634-A1 HIGHLY ATOM ECONOMICAL PROCESS FOR SYNTHESIS OF NOVEL CO-INITIATOR FOR PHOTO-INDUCED RADICAL POLYMERISATION SHIV NADAR (INSTITUTION OF EMINENCE DEEMED TO BE UNIVERSITY) (IN) 2024-09-19 WO disclosed
EP-4430131-A1 COMPOSITION Merck Patent GmbH (DE) 2024-09-18 EP disclosed
CN-117836392-A Biological oil fraction composition derived from biological oil 苏扎诺公司 2024-04-05 CN disclosed
US-11939691-B2 Tin or tin alloy electroplating bath, and electronic component having electrodeposit formed thereon using the plating bath ISHIHARA CHEMICAL CO., LTD. (JP) 2024-03-26 US disclosed
CN-112041296-B Aminoacetamides containing benzooxy alicyclic structures and uses thereof 上海璃道医药科技有限公司 2023-12-29 CN disclosed
WO-2023083834-A1 COMPOSITION MERCK PATENT GMBH (DE) 2023-05-19 WO disclosed
EP-4126835-A1 INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR Janssen Pharmaceutica NV (BE) 2023-02-08 EP disclosed
US-20230001543-A1 BONDED ABRASIVE ARTICLE AND METHOD OF MAKING THE SAME 3M INNOVATIVE PROPERTIES COMPANY 2023-01-05 US disclosed
EP-4076841-A1 BONDED ABRASIVE ARTICLE AND METHOD OF MAKING THE SAME 3M Innovative Properties Company (US) 2022-10-26 EP disclosed
EP-4021510-A2 CONJUGATES AND CONJUGATES FOR USE IN PREVENTING OR TREATING OF BRAIN DAMAGE AND NEURODEGENERATIVE DISEASES Medicortex Finland Oy (FI) 2022-07-06 EP disclosed
CN-112844379-B Method for preparing monophenol chemicals by catalyzing lignin depolymerization through ruthenium loaded on metal organic framework material derivative 华南理工大学 2022-06-14 CN disclosed
US-20220125766-A1 METHODS FOR TREATING CONGENITAL DISORDERS OF GLYCOSYLATION MAGGIES PEARL LLC (US) 2022-04-28 US disclosed
EP-3987086-A1 METHOD FOR PREPARING HIGH-CONCENTRATION PENTA-TWINNED GOLD NANOPARTICLES Université Claude Bernard Lyon 1 (FR) 2022-04-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220125766-A1 METHODS FOR TREATING CONGENITAL DISORDERS OF GLYCOSYLATION MAN1B1, MAN2B1, GAA TP53 2399/4885ALDH1A1 1692/4885LMNA 1508/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.